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actual indication for protons thus heavily rests on individual 
clinical and patient dependent a priori risk factors.  
 
 
 
 
Conclusion: These results demonstrate that the potential of 
proton therapy to reduce the risk of radiation pneumonitis 
requires considerable reduction in lung dose, but translation 
into clinical significance is heavily driven by patient and 
clinical a priori risk factors. Therefore, multivariable NTCP 
models should play a major role in identifying patients 
eligible for proton therapy. 
1 Appelt, Vogelius, Farr, Khalik, Bentzen. Towards 
individualized dose constraints: adjusting the QUANTEC 
radiation pneumonitis model for clinical risk factors. Acta 
Oncologica 2014;53:605. 
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Purpose or Objective: The purpose of this study is to provide 
a dosimetric assessment for the feasibility of delivering lung 
SBRT using an integrated three-source Co60 and Magnetic 
Resonance Imaging (MRI) Guided Radiation Therapy (MR-IGRT) 
System. 
 
Material and Methods: Ten lung patients who were 
previously treated with Linac-based SBRT were included. For 
each patient, GTV, PTV, cord, lungs, heart, esophagus, and 
ribs were delineated. All Linac-based SBRT plans were 
generated using VMAT and consist of 2-10 6MV Rapid Arcs. 
Patients received prescription doses of 48 Gy/4fx to 50 
Gy/5fx. The Linac-based plans were imported into the View 
Ray MR-IGRT system for planning. Three-source Co60 plans 
were generated using step-and-shoot IMRT and utilized Monte 
Carlo dose calculation including the magnetic field correction 
of 0.35T. The PTV coverage for both Linac-based three-
source Co60 SBRT plans were such that 95% of the PTV 
received 100% the prescription dose. Finally, Linac- and three 
source Co60 – based plans were evaluated using dose-volume 
constraints for critical structures and target conformity index 
(CI), homogeneity index (HI) for the PTV. 
 
Results: The differences between PTV HI for Linac- and 
three-source Co60 -based SBRT plans were not statistically 
significant, ranging from 1.05 to 1.15. Three patients with 
the CIs >1.2 had target volumes <20cc although the location 
of the target did not have much influence on meeting the 
criteria for the target conformity. For all patients, the 
critical structure doses, such as maximum cord dose (<26 
Gy), dose to <15 cc of the heart (28Gy<15cc), and <5cc of the 
esophagus (18.8 Gy<5cc) were satisfactory with both 
techniques. For lung, although both the dose to <1500cc 
(11.6 Gy<1500cc) and <1000cc (13.6Gy<1000cc) criteria were 
met with both techniques, on average, the lung volumes 
receiving the 11.6Gy and 13.6Gy were 59.5% and 61.28% 
higher with three-source Co60 as compared the Linac-based 
SBRT plans respectively (P<0.05). As expected, low dose 
portion of the DVH for all critical structures generally 
covered much higher percentage of the critical structure 
volumes with three-source Co60 SBRT plans as compared to 
the Linac-based SBRT plans. 
 
 
Conclusion: Overall, a three-source Co60 integrated MR-IGRT 
system produced comparable dose distributions to the ones 
obtained with the Linac-based lung SBRT. Further studies are 
needed to evaluate benefits of this novel MR-IGRT system for 
lung SBRT, especially its ability to image and plan in real 
time and online adaptive treatment delivery. 
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Purpose or Objective: To experimentally validate a 4D 
Monte Carlo (MC) simulation method to calculate the dose 
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delivered by an Elekta Agility linear accelerator to a moving 
anatomy.  
 
Material and Methods: A Quasar respiratory motion 
programmable phantom (Modus Medical) with a lung insert 
containing a 3 cm diameter tumour was used for dose 
measurements. Measurements were performed on an Elekta 
Agility linac with the phantom in static and moving 
(sinusoidal motion, 1.8 cm respiratory amplitude) states. 
Dose to the centre of the tumor was measured using 
calibrated EBT3 film and the RADPOS 4D dosimetry system. 
The RADPOS position tracker recorded the phantom motion 
with time steps of 100 ms. Static and 4DCT scans of the 
Quasar phantom were acquired using a helical CT scanner 
(Brilliance CT Big Bore). A single 6 MV 4x4 cm2 square field 
covering the tumour was planned on the static CT scans using 
the Elekta XiO V.4.7 treatment planning system. A previously 
validated BEAMnrc model of our Elekta Agility linac was used 
for all simulations. The DOSXYZnrc and defDOSXYZnrc user 
codes were used, respectively, for static and moving anatomy 
dose simulations with 500,000,000 histories to achieve a 
statistical uncertainty of 0.4%. The defDOSXYZnrc code was 
modified to sample a new geometry for each incident 
particle, thereby simulating the continuous phantom motion. 
The treatment plan was exported from XiO as DICOM format 
and a Python script was used to extract the data and 
generate input files for MC simulations. An egsphant file with 
0.1250 x 0.1250 x 0.1 cm3 resolution was generated from 
static CT scans for all simulations. The multipass deformable 
image registration algorithm in Velocity (Varian Medical 
Systems) V.3.0.1 was used to register the CT image of the 
phantom in end-of-exhale state to the static CT image. For 
4D simulations, deformation vectors from Velocity were input 
to the defDOSXYZnrc code as well as the phantom motion 
trace measured with RADPOS. To examine the impact of 
deformable registration accuracy, 4D simulations were also 
performed using manually generated deformation vectors 
that exactly modelled the rigid translation of the lung insert.  
 
Results: Table 1 shows the calculated and measured tumor 
doses and their uncertainties. Calculated dose for the moving 
anatomy using vectors generated by Velocity was 75.9 
cGy±0.4% that is 0.5% lower than the similar calculation using 
manually generated vectors. 
Table 1. Calculated and measured tumor doses and their 
uncertainties 
 
 
Figure 1 shows the calculated and measured tumor profiles
 
 
Fig1. Comparison of simulated (MC with manually generated 
vectors) and measured (Film) dose profiles for static (left) 
and moving (right) states.  
. 
Conclusion: The level of agreement between MC Simulation 
results and measurements is within 2%. This makes our 4D 
Monte Carlo simulations using the defDOSXYZnrc code an 
accurate and reliable method to calculate dose delivered to a 
moving anatomy. 
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Purpose or Objective: Determining whether individual 
treatment plans are near optimal is important for routine 
clinical care and clinical studies. However, plan quality 
assurance (QA) is difficult, time consuming and operator 
dependent. Furthermore, applying checklists of generic QA 
parameters to all patients cannot accurately gauge the 
quality of individual patient plans. RapidPlan (Varian Medical 
Systems, Palo Alto, USA), a commercial knowledge-based 
planning solution, could automate individualized plan QA by 
benchmarking the plan against predicted patient-specific 
organ-at-risk (OAR) doses derived from a library of plans that 
consists of various OAR-planning target volume (PTV) 
geometries and associated dose distributions. Using 
RapidPlan for this purpose requires that the predicted doses 
are achievable when RapidPlan is subsequently used to 
generate a plan. This was investigated for locally advanced 
head and neck cancer. 
 
Material and Methods: A RapidPlan model consisting of 90 
plans, generated using previously created automatically 
optimized plans, was used to predict achievable OAR dose-
volume histograms (DVHs) for the parotid glands, 
submandibular glands, individual swallowing muscles and oral 
cavities of 20 HNC patients. Differences between the 
achieved and predicted DVH-lines were analyzed for all OARs. 
To illustrate the possible gains that individualized plan QA 
could realize, the RapidPlan predictions were used to 
evaluate achieved OAR sparing of an evaluation group (EG) of 
20 manually interactively optimized plans. 
 
Results: The Figure shows strong linear correlations (solid 
lines, R²=0.94-0.99) found between the predicted and 
achieved mean doses for all OARs, demonstrating the 
accuracy of the RapidPlan DVH predictions. The dashed lines 
have a slope of 1 and run through the origin, meaning that 
for OARs on this line, the mean dose predicted by RapidPlan 
was exactly achieved. More detailed analysis of the predicted 
and achieved DVHs showed that at higher dose regions (OAR 
volumes <30%), the amount of achievable sparing is 
underestimated for OARs with mean doses <20Gy while it is 
progressively overestimated for OARs with higher mean 
doses. Using the predicted OAR DVHs identified that for 10 
plans in the EG, sparing of the composite (volume weighted) 
salivary glands, oral cavity or composite swallowing muscles 
could be improved by at least 3Gy, 5Gy or 7Gy, respectively. 
These predicted gains were confirmed by replanning the 
identified patients using RapidPlan. 
 
